Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway
Background: Doxorubicin (Dox) can induce endotheliotoxicity and damage the vascular endothelium (VE). The most principle mechanism might be excess reactive oxygen species (ROS) generation. Nevertheless, the characteristics of ROS generation, downstream mechanisms, and target organelles in Dox-induce...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01531/full |
id |
doaj-ec0890de18aa4277a14d6a836a7234c0 |
---|---|
record_format |
Article |
spelling |
doaj-ec0890de18aa4277a14d6a836a7234c02020-11-25T02:55:44ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-01-011010.3389/fphar.2019.01531485392Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO PathwayHuan He0Huan He1Liang Wang2Yang Qiao3Qing Zhou4Hongwei Li5Shuping Chen6Dong Yin7Qing Huang8Ming He9Jiangxi Provincial Institute of Hypertension, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaDepartment of Rehabilitation, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang, ChinaJiangxi Provincial Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaJiangxi Provincial Institute of Cardiovascular Diseases, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, ChinaJiangxi Provincial Institute of Hypertension, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaBackground: Doxorubicin (Dox) can induce endotheliotoxicity and damage the vascular endothelium (VE). The most principle mechanism might be excess reactive oxygen species (ROS) generation. Nevertheless, the characteristics of ROS generation, downstream mechanisms, and target organelles in Dox-induced endotheliotoxicity have yet to be elucidated.Methods and Results: In order to explore the related problems, the VE injury models were established in mice and human umbilical vein endothelial cells (HUVECs) by Dox-induced endotheliotoxicity. Results showed that the activities of lactate dehydrogenase (LDH) and creatine kinase of mice’s serum increased after injected Dox. The thoracic aortic strips’ endothelium-dependent dilation was significantly impaired, seen noticeable inflammatory changes, and brown TUNEL-positive staining in microscopy. After Dox-treated, HUVECs viability lowered, LDH and caspase-3 activities, and apoptotic cells increased. Both intracellular/mitochondrial ROS generation significantly increased, and intracellular ROS generation lagged behind mitochondria. HUVECs treated with Dox plus ciclosporin A (CsA) could basically terminate ROS burst, but plus edaravone (Eda) could only delay or inhibit, but could not completely cancel ROS burst. Meanwhile, the expression of endothelial nitric oxide synthase (eNOS) decreased, especially phosphorylation of eNOS significantly. Then nitric oxide content decreased, the mitochondrial function was impaired, mitochondrial membrane potential (MMP) impeded, mitochondrial swelled, mitochondrial permeability transition pore (mPTP) was opened, and cytochrome C was released from mitochondria into the cytosol.Conclusion: Dox produces excess ROS in the mitochondria, thereby weakens the MMP, opens mPTP, activates the ROS-induced ROS release mechanism, induces ROS burst, and leads to mitochondrial dysfunction, which in turn damages VE. Therefore, interrupting any step of the cycles, as mentioned above can end the related vicious cycle and prevent the occurrence and development of injury.https://www.frontiersin.org/article/10.3389/fphar.2019.01531/fulldoxorubicinvascular endotheliumendotheliotoxicitymitochondriaROS/eNOS/NO pathway |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Huan He Huan He Liang Wang Yang Qiao Qing Zhou Hongwei Li Shuping Chen Dong Yin Qing Huang Ming He |
spellingShingle |
Huan He Huan He Liang Wang Yang Qiao Qing Zhou Hongwei Li Shuping Chen Dong Yin Qing Huang Ming He Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway Frontiers in Pharmacology doxorubicin vascular endothelium endotheliotoxicity mitochondria ROS/eNOS/NO pathway |
author_facet |
Huan He Huan He Liang Wang Yang Qiao Qing Zhou Hongwei Li Shuping Chen Dong Yin Qing Huang Ming He |
author_sort |
Huan He |
title |
Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway |
title_short |
Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway |
title_full |
Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway |
title_fullStr |
Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway |
title_full_unstemmed |
Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway |
title_sort |
doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ros/enos/no pathway |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-01-01 |
description |
Background: Doxorubicin (Dox) can induce endotheliotoxicity and damage the vascular endothelium (VE). The most principle mechanism might be excess reactive oxygen species (ROS) generation. Nevertheless, the characteristics of ROS generation, downstream mechanisms, and target organelles in Dox-induced endotheliotoxicity have yet to be elucidated.Methods and Results: In order to explore the related problems, the VE injury models were established in mice and human umbilical vein endothelial cells (HUVECs) by Dox-induced endotheliotoxicity. Results showed that the activities of lactate dehydrogenase (LDH) and creatine kinase of mice’s serum increased after injected Dox. The thoracic aortic strips’ endothelium-dependent dilation was significantly impaired, seen noticeable inflammatory changes, and brown TUNEL-positive staining in microscopy. After Dox-treated, HUVECs viability lowered, LDH and caspase-3 activities, and apoptotic cells increased. Both intracellular/mitochondrial ROS generation significantly increased, and intracellular ROS generation lagged behind mitochondria. HUVECs treated with Dox plus ciclosporin A (CsA) could basically terminate ROS burst, but plus edaravone (Eda) could only delay or inhibit, but could not completely cancel ROS burst. Meanwhile, the expression of endothelial nitric oxide synthase (eNOS) decreased, especially phosphorylation of eNOS significantly. Then nitric oxide content decreased, the mitochondrial function was impaired, mitochondrial membrane potential (MMP) impeded, mitochondrial swelled, mitochondrial permeability transition pore (mPTP) was opened, and cytochrome C was released from mitochondria into the cytosol.Conclusion: Dox produces excess ROS in the mitochondria, thereby weakens the MMP, opens mPTP, activates the ROS-induced ROS release mechanism, induces ROS burst, and leads to mitochondrial dysfunction, which in turn damages VE. Therefore, interrupting any step of the cycles, as mentioned above can end the related vicious cycle and prevent the occurrence and development of injury. |
topic |
doxorubicin vascular endothelium endotheliotoxicity mitochondria ROS/eNOS/NO pathway |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.01531/full |
work_keys_str_mv |
AT huanhe doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT huanhe doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT liangwang doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT yangqiao doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT qingzhou doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT hongweili doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT shupingchen doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT dongyin doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT qinghuang doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway AT minghe doxorubicininducesendotheliotoxicityandmitochondrialdysfunctionviarosenosnopathway |
_version_ |
1724716557081247744 |